![How Elite Institutions were Affected By a Decade of Constricted Funding](https://cdn.cancerletter.com/media/2024/01/01224843/40-42-NCI-funding.png)
![How Elite Institutions were Affected By a Decade of Constricted Funding](https://cdn.cancerletter.com/media/2024/01/01224843/40-42-NCI-funding.png)
Cover Story
Free
By Will Craft and Matthew Bin Han Ong
The ten-year period of erosion that followed the doubling of the NIH budget has hit some research institutions harder than others.
In Brief
![In Brief](https://cdn.cancerletter.com/media/2019/05/03155624/in-brief-3.jpg)
![In Brief](https://cdn.cancerletter.com/media/2019/05/03155624/in-brief-3.jpg)
Funding Opportunities
Drugs & Targets
![Drugs & Targets](https://cdn.cancerletter.com/media/2019/05/03161633/targets2.jpg)
![Drugs & Targets](https://cdn.cancerletter.com/media/2019/05/03161633/targets2.jpg)
Trending Stories
- Federal judge blocks Trump administration’s move to limit indirect costs to 15% for NIH-funded institutions
The move could gut academic cancer research - FDA grants Cytotron Breakthrough Device Designation for breast, liver and pancreatic cancers
- What Trump’s pick of RFK Jr. means for cancer: Epidemics, HPV, stunted research
Former FDA Commissioner Scott Gottlieb expresses “deep concerns” - “Page Not Found:” HHS agencies purge web pages that hint at DEI, health equity, and gender
Medical group sues over removing “information used every day by health professions” - Beyond the $500B Stargate Project: The frontier of AI in oncology beckons
- Pediatric cancer research cut from spending legislation at last minute
Republicans quietly removed hard-won pediatric cancer bills